Phase I Trial of Pembrolizumab for Neurological Symptoms Post-COVID-19
A Phase I open-label trial is underway to evaluate the safety of pembrolizumab in patients with neurological symptoms following COVID-19.
Therapeutic Area
Therapeutic area intelligence for Post-Acute Sequelae of SARS-CoV-2 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.